# New Data for Precision Biologics, Inc. PB-223 ADC against novel tumor-specific target on human cancers revealed at SITC 2026

- Source: PR Newswire M&A
- Published: 2026-11-06T14:18:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/new-data-for-precision-biologics-inc-pb-223-adc-against-novel-tumor-specific-target-on-human-cancers-revealed-at-sitc-2026-302925091.html
- Canonical: https://groundlevelnews.com/story/new-data-for-precision-biologics-inc-pb-223-adc-against-novel-tumor-sp-5855ad/

BETHESDA, Md., Nov. 6, 2026 /PRNewswire/ -- Precision Biologics, Inc. CEO Philip M. Arlen, MD announces presentation of new data describing in-vivo efficacy of its novel tumor-specific antibody-drug-conjugate PB-223 ADC. Recent tumor killing data showing specific non-toxic anti-tumor...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._